PGNY Quote, Financials, Valuation and Earnings

Clover Health Investments Corp. has a net margin of 3.92% compared to Progyny, Inc.'s net margin of -10.11%. Progyny, Inc.'s return on equity of 11.8% beat Clover Health Investments Corp.'s return on equity of -25.6%.

Progyny, Inc. has a consensus price target of $29.64, signalling upside risk potential of 69.16%. On the other hand Clover Health Investments Corp. has an analysts' consensus of $3.15 which suggests that it could grow by 57.5%. Given that Progyny, Inc. has higher upside potential than Clover Health Investments Corp., analysts believe Progyny, Inc. is more attractive than Clover Health Investments Corp..

Progyny, Inc. has a beta of 1.013, which suggesting that the stock is 1.34% more volatile than S&P 500. In comparison Clover Health Investments Corp. has a beta of 2.149, suggesting its more volatile than the S&P 500 by 114.867%.

Progyny, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Clover Health Investments Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Progyny, Inc. pays -- of its earnings as a dividend. Clover Health Investments Corp. pays out -- of its earnings as a dividend.

Progyny, Inc. quarterly revenues are $318.4M, which are smaller than Clover Health Investments Corp. quarterly revenues of $487.7M. Progyny, Inc.'s net income of $12.5M is higher than Clover Health Investments Corp.'s net income of -$49.3M. Notably, Progyny, Inc.'s price-to-earnings ratio is 26.84x while Clover Health Investments Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Progyny, Inc. is 1.22x versus 0.53x for Clover Health Investments Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Centene Corp. has a net margin of 3.92% compared to Progyny, Inc.'s net margin of -2.21%. Progyny, Inc.'s return on equity of 11.8% beat Centene Corp.'s return on equity of -27.11%.

Progyny, Inc. has a consensus price target of $29.64, signalling upside risk potential of 69.16%. On the other hand Centene Corp. has an analysts' consensus of $44.35 which suggests that it could grow by 1.22%. Given that Progyny, Inc. has higher upside potential than Centene Corp., analysts believe Progyny, Inc. is more attractive than Centene Corp..

Progyny, Inc. has a beta of 1.013, which suggesting that the stock is 1.34% more volatile than S&P 500. In comparison Centene Corp. has a beta of 0.480, suggesting its less volatile than the S&P 500 by 51.962%.

Progyny, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Centene Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Progyny, Inc. pays -- of its earnings as a dividend. Centene Corp. pays out -- of its earnings as a dividend.

Progyny, Inc. quarterly revenues are $318.4M, which are smaller than Centene Corp. quarterly revenues of $49.7B. Progyny, Inc.'s net income of $12.5M is higher than Centene Corp.'s net income of -$1.1B. Notably, Progyny, Inc.'s price-to-earnings ratio is 26.84x while Centene Corp.'s PE ratio is 8.66x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Progyny, Inc. is 1.22x versus 0.11x for Centene Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Molina Healthcare, Inc. has a net margin of 3.92% compared to Progyny, Inc.'s net margin of -1.41%. Progyny, Inc.'s return on equity of 11.8% beat Molina Healthcare, Inc.'s return on equity of 10.89%.

Progyny, Inc. has a consensus price target of $29.64, signalling upside risk potential of 69.16%. On the other hand Molina Healthcare, Inc. has an analysts' consensus of $157.56 which suggests that it could grow by 8.81%. Given that Progyny, Inc. has higher upside potential than Molina Healthcare, Inc., analysts believe Progyny, Inc. is more attractive than Molina Healthcare, Inc..

Progyny, Inc. has a beta of 1.013, which suggesting that the stock is 1.34% more volatile than S&P 500. In comparison Molina Healthcare, Inc. has a beta of 0.518, suggesting its less volatile than the S&P 500 by 48.232%.

Progyny, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Molina Healthcare, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Progyny, Inc. pays -- of its earnings as a dividend. Molina Healthcare, Inc. pays out -- of its earnings as a dividend.

Progyny, Inc. quarterly revenues are $318.4M, which are smaller than Molina Healthcare, Inc. quarterly revenues of $11.4B. Progyny, Inc.'s net income of $12.5M is higher than Molina Healthcare, Inc.'s net income of -$160M. Notably, Progyny, Inc.'s price-to-earnings ratio is 26.84x while Molina Healthcare, Inc.'s PE ratio is 16.93x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Progyny, Inc. is 1.22x versus 0.17x for Molina Healthcare, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Oscar Health, Inc. has a net margin of 3.92% compared to Progyny, Inc.'s net margin of -12.56%. Progyny, Inc.'s return on equity of 11.8% beat Oscar Health, Inc.'s return on equity of -40.11%.

Progyny, Inc. has a consensus price target of $29.64, signalling upside risk potential of 69.16%. On the other hand Oscar Health, Inc. has an analysts' consensus of $15.40 which suggests that it could grow by 12.66%. Given that Progyny, Inc. has higher upside potential than Oscar Health, Inc., analysts believe Progyny, Inc. is more attractive than Oscar Health, Inc..

Progyny, Inc. has a beta of 1.013, which suggesting that the stock is 1.34% more volatile than S&P 500. In comparison Oscar Health, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Progyny, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oscar Health, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Progyny, Inc. pays -- of its earnings as a dividend. Oscar Health, Inc. pays out -- of its earnings as a dividend.

Progyny, Inc. quarterly revenues are $318.4M, which are smaller than Oscar Health, Inc. quarterly revenues of $2.8B. Progyny, Inc.'s net income of $12.5M is higher than Oscar Health, Inc.'s net income of -$352.4M. Notably, Progyny, Inc.'s price-to-earnings ratio is 26.84x while Oscar Health, Inc.'s PE ratio is 51.21x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Progyny, Inc. is 1.22x versus 0.32x for Oscar Health, Inc.. Usually stocks with elevated PS ratios are considered overvalued.